This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lablanche, J.-M. Articles by Bertrand, M. E. Search for Related Content PubMed PubMed Citation Articles by Lablanche, J.-M. Articles by Bertrand, M. E. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Angioplasty Blood Thinners

(Circulation. 1997;96:3396-3402.)
© 1997 American Heart Association, Inc.

Articles

Effect of Nadroparin, a Low-Molecular-Weight Heparin, on Clinical and Angiographic Restenosis After Coronary Balloon Angioplasty

The FACT Study

Jean-Marc Lablanche, MD; Eugène P. McFadden, MRCPI; Nicolas Meneveau, MD; Jean René Lusson, MD; Bernard Bertrand, MD; Jean-Philippe Metzger, MD; Victor Legrand, MD; Gilles Grollier, MD; Carlos Macaya, MD; Bernard de Bruyne, MD; Alec Vahanian, MD; Alain Grentzinger, MD; Christiane Masquet, MD; Jean-Eric Wolf, MD; Gerard Tobelem, MD; Sylvie Fontecave, MD; André Vacheron, MD; Pascal d'Azemar, MD; ; Michel E. Bertrand, MD

From the Centre Hospitalier Regional et Universitaire Lille, France (J.-M.L., E.P.M., M.E.B.); Centre Hospitalier Regional et Universitaire Besançon, France (N.M.); Centre Hospitalier Regional et Universitaire, Clermont-Ferrand, France (J.R.L.); Centre Hospitalier Regional et Universitaire, Grenoble, France (B.B.); Groupe Hospitalier Necker-Enfants Malades, Paris, France (J.-P.M., A.V.); Centre Hospitalier Universitaire de Liège, Belgium (V.L.); Centre Hospitalier Regional, Caen, France (G.G.); San Carlos University Hospital, Madrid, Spain (C.M.); O.L. Vrouwziekenhuis, Aalst, Belgium (B. de B.); Hôpital Tenon, Paris, France (A.V.); Centre Hospitalier Universitaire de Brabois, Vandoeuvre Les Nancy, France (A.G.); Hôpital Lariboisière, Paris, France (C.M., G.T.); Centre Hospitalier Universitaire, Dijon, France (J.-E.W.); Sanofi Research, Paris, France (S.F., P d'A.).

Correspondence to J.-M. Lablanche, MD, Service de cardiologie C, Hopital Cardiologique, 59037 Lille, France.

Background Experimental studies suggest that the antiproliferative effect of heparin after arterial injury is maximized by pretreatment. No previous studies of restenosis have used a pretreatment strategy. We designed this study to determine whether treatment with nadroparin, a low-molecular-weight heparin, started 3 days before the procedure and continued for 3 months, affected angiographic restenosis or clinical outcome after coronary angioplasty.

Methods and Results In a prospective multicenter, double-blind, randomized trial, elective coronary angioplasty was performed on 354 patients who were treated with daily subcutaneous nadroparin (0.6 mL of 10 250 anti-Xa IU/mL) or placebo injections started 3 days before angioplasty and continued for 3 months. Angiography was performed just before and immediately after angioplasty and at follow-up. The primary study end point was angiographic restenosis, assessed by quantitative coronary angiography 3 months after balloon angioplasty. Clinical follow-up was continued up to 6 months. Clinical and procedural variables and the occurrence of periprocedural complications did not differ between groups. At angiographic follow-up, the mean minimal lumen diameter and the mean residual stenosis in the nadroparin group (1.37±0.66 mm, 51.9±21.0%) did not differ from the corresponding values in the control group (1.48±0.59 mm, 48.8±18.9%). Combined major cardiac-related clinical events (death, myocardial infarction, target lesion revascularization) did not differ between groups (30.3% versus 29.6%).

Conclusions Pretreatment with the low-molecular-weight heparin nadroparin continued for 3 months after balloon angioplasty had no beneficial effect on angiographic restenosis or on adverse clinical outcomes.

Key Words: angioplasty • anticoagulants • aspirin • heparin

This article has been cited by other articles:

				R. A. Harrington, R. C. Becker, C. P. Cannon, D. Gutterman, A. M. Lincoff, J. J. Popma, G. Steg, G. H. Guyatt, and S. G. Goodman Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 670S - 707S. [Abstract] [Full Text] [PDF]

				J. J. Popma, P. Berger, E. M. Ohman, R. A. Harrington, C. Grines, and J. I. Weitz Antithrombotic Therapy During Percutaneous Coronary Intervention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 576S - 599S. [Abstract] [Full Text] [PDF]

				J.-F. Deux, A. Meddahi-Pelle, A. F. Le Blanche, L. J. Feldman, S. Colliec-Jouault, F. Bree, F. Boudghene, J.-B. Michel, and D. Letourneur Low Molecular Weight Fucoidan Prevents Neointimal Hyperplasia in Rabbit Iliac Artery In-Stent Restenosis Model Arterioscler. Thromb. Vasc. Biol., October 1, 2002; 22(10): 1604 - 1609. [Abstract] [Full Text] [PDF]

				M. T. Osinski, B. H. Rauch, and K. Schrör Antimitogenic Actions of Organic Nitrates Are Potentiated by Sildenafil and Mediated Via Activation of Protein Kinase A Mol. Pharmacol., April 16, 2001; 59(5): 1044 - 1050. [Abstract] [Full Text]

				J. Ph. Collet, G. Montalescot, L. Lison, R. Choussat, A. Ankri, G. Drobinski, I. Sotirov, and D. Thomas Percutaneous Coronary Intervention After Subcutaneous Enoxaparin Pretreatment in Patients With Unstable Angina Pectoris Circulation, February 6, 2001; 103(5): 658 - 663. [Abstract] [Full Text] [PDF]

				G. G Nenci and A. Minciotti Low molecular weight heparins for arterial thrombosis Vascular Medicine, November 1, 2000; 5(4): 251 - 258. [Abstract] [PDF]

				N Meneveau, F Schiele, G Grollier, B Farah, J.M Lablanche, K Khalife, J Machecourt, N Danchin, J.E Wolf, M Simpson, et al. Local delivery of nadroparin for the prevention of neointimal hyperplasia following stent implantation: results of the IMPRESS Trial. A multicentre, randomized, clinical, angiographic and intravascular ultrasound study Eur. Heart J., November 1, 2000; 21(21): 1767 - 1775. [Abstract] [PDF]

				S. Kageyama, H. Yamamoto, and R. Yoshimoto Anti-Human von Willebrand Factor Monoclonal Antibody AJvW-2 Prevents Thrombus Deposition and Neointima Formation After Balloon Injury in Guinea Pigs Arterioscler. Thromb. Vasc. Biol., October 1, 2000; 20(10): 2303 - 2308. [Abstract] [Full Text] [PDF]

				F. D. Kolodgie, A. Farb, and R. Virmani Local Delivery of Ceramide for Restenosis : Is There a Future for Lipid Therapy? Circ. Res., August 18, 2000; 87(4): 264 - 267. [Full Text] [PDF]

				D. S Ettenson and E. R Edelman Local drug delivery: an emerging approach in the treatment of restenosis Vascular Medicine, May 1, 2000; 5(2): 97 - 102. [Abstract] [PDF]

				C. E. Hart, L. W. Kraiss, S. Vergel, D. Gilbertson, R. Kenagy, T. Kirkman, D. L. Crandall, S. Tickle, H. Finney, G. Yarranton, et al. PDGFß Receptor Blockade Inhibits Intimal Hyperplasia in the Baboon Circulation, February 2, 1999; 99(4): 564 - 569. [Abstract] [Full Text] [PDF]